Latest news with #drugDiscovery
National Post
28-05-2025
- Business
- National Post
Conscience Welcomes Peng Fu as New CEO
Article content Mr. Fu brings extensive financial and biotech experience to role as the nonprofit expands its innovative platform to address unmet needs in drug discovery and development through open science. Article content Article content TORONTO — Conscience, a non-profit that uses open science and true collaboration to enable drug discovery and development where market solutions are limited, is pleased to announce the appointment of Peng Fu as its new Chief Executive Officer (CEO), effective immediately. Mr. Fu succeeds inaugural CEO, Ryan Merkley, who as previously announced, departed the organization in early 2025. Article content Mr. Fu stepping in as Conscience's new CEO marks a milestone in the organization's strategic evolution. 'We are thrilled to welcome Peng Fu to the leadership team at Conscience during an integral time in our organization,' said Anke Mueller-Fahrnow, Chair of Conscience's Board of Directors. 'Peng's entrepreneurial mindset, investment expertise, and science and legal background are key to taking Conscience to the next stage. We are confident that he is the right person for this role. We look forward to working with Peng and bringing further awareness to the importance of open science in enabling drug discovery and development, so that we can achieve better health outcomes for all.' Article content Mr. Fu joins Conscience with an impressive range of biotech, financing and executive experience. He is the founder of Novatio Ventures, an investment and advisory firm that accelerates the commercialization of high-potential life science innovations through incubation of early stage technologies and provision of bespoke financing solutions to growth stage companies. Mr. Fu is also a board member and founding investor of 3io Therapeutics and Precision Proteomics, two Canadian companies developing technologies licensed from Canadian institutions. He previously served as Managing Director and Partner at CBC Group and LYFE Capital, respectively, two leading global healthcare private equity firms. Earlier, Mr. Fu was Vice President, Business Development at DRI Capital (now DRI Healthcare), Director, Senior Counsel and member of the Executive Committee at Amgen Canada, and Director, Legal Affairs at Teva Pharmaceuticals. Mr. Fu began his career as a life science attorney in private practice at Torys and Gilbert's LLP in Toronto. He holds an MSc degree in biology from the University of Toronto and a JD degree in law from Queen's University. Article content 'Conscience views science as a team sport and I am excited to be joining this exceptional team as we work together to use AI and open science to advance drug discovery,' said Peng Fu, CEO of Conscience. 'In only a few years, the team has built a solid foundation with an expansive network of partners, and has launched several key initiatives, including the CACHE (Critical Assessment of Computational Hit-Finding Experiments) Challenges and DMOS (Developing Medicines through Open Science) program. I look forward to building on this foundation and expanding our platform in the years ahead.' Article content Conscience is a non-profit focused on enabling drug discovery and development in areas where open sharing and collaboration are key to advancement and where market solutions are limited, such as rare or neglected diseases, pandemic preparedness, and antimicrobial resistance. It does so by encouraging teamwork, the open sharing of knowledge and tools, the use and improvement of artificial intelligence, and the development of policies that break down barriers of traditional drug development models. Powered by a network that includes academics, industry, technologists, policy experts, and public support, Conscience seeks to drive innovation by turning drug discovery and development into a team sport. Through key initiatives, such as its DMOS (Developing Medicines through Open Science) program and CACHE (Critical Assessment of Computation Hit-finding Experiments) Challenges, Conscience is accelerating the path to treatments for those who need them most so no patient is left behind. For more information, visit Article content Article content Article content Article content Article content Article content
Yahoo
21-05-2025
- Business
- Yahoo
High Content Screening (HCS) Business Analysis Report 2025: Global Market to Reach $2.2 Billion by 2030 - Rising Investments in Biotechnology and Life Sciences Expands Scope
The global High Content Screening (HCS) market is forecast to grow from USD 1.3 billion in 2024 to USD 2.2 billion by 2030, driven by advancements in imaging and personalized medicine. HCS enhances drug discovery by enabling real-time cellular analysis, crucial for cancer research and therapeutic development. Key market segments include Instruments and Consumables with notable growth in regions like the U.S. and China. This report offers insights into market trends, drivers, regional performances, and competitive landscapes, aiding strategic business decisions. High Content Screening (HCS) Market Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "High Content Screening (HCS) - Global Strategic Business Report" report has been added to global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the High Content Screening (HCS) market. High Content Screening (HCS) is revolutionizing the field of biological research and drug discovery by enabling detailed observations of cellular processes in real-time, particularly enhancing the development of personalized medicine. HCS utilizes advanced imaging and analysis techniques to study the effects of various compounds on cells, offering insights far beyond traditional methodologies that used isolated cells. This technique is becoming increasingly pivotal, especially with its application in living multicellular structures like organoids or tissue sections, which more accurately simulate biological interactions within organisms. This nuanced observation at the cellular level allows for a deeper understanding of the cellular dynamics that characterize health and disease states, pushing forward the boundaries of biomedical research and therapeutic the realm of cancer research, HCS has proven invaluable. Traditional models that cultivate tumor cells in artificial environments can induce unnatural behaviors; however, HCS addresses this by using environments that include an extracellular matrix, leading to more natural cellular behavior and responses. This setup allows for the creation of microtissues that closely mimic natural tumor environments, which are then tested against various drugs using automated microscopy and sophisticated image analysis. This phenotypic screening helps to personalize treatment by identifying how individual cells within a tumor respond to specific drugs, highlighting the variability in drug resistance and efficacy. This method significantly refines our understanding of cancer cell dynamics and is instrumental in crafting more effective and personalized treatment regimens, thus minimizing the trial-and-error often associated with cancer integration of HCS into clinical practice, however, faces significant challenges, primarily due to the complexities involved in maintaining accurate 3D cultures and the analysis of large datasets they generate. Despite these hurdles, technological advancements are facilitating the miniaturization of tissue-like structures suitable for high-throughput screening, enhancing the scalability of HCS applications. Key growth drivers for HCS include the integration with multicellular and 3D models, advancements in imaging technologies, and the development of automated analysis software. Additionally, the increasing emphasis on personalized medicine and the expansion of drug discovery efforts demand more effective screening technologies like HCS. Regulatory support for predictive models and consumer demand for quicker, more accurate testing methods also significantly contribute to the broader adoption and ongoing development of HCS, underscoring its growing impact on the fields of drug development and personalized ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 9.4%. The Consumables segment is also set to grow at 8.2% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $332.6 Million in 2024, and China, forecasted to grow at an impressive 12.3% CAGR to reach $492.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as BD Biosciences, BioTek Instruments Inc., EMD Millipore, Essen BioScience, Evotec AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 183 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.3 Billion Forecasted Market Value (USD) by 2030 $2.2 Billion Compound Annual Growth Rate 9.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Global Economic Update High Content Screening (HCS) - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Drug Discovery and Development Propels Growth in HCS Market Advances in Imaging Technologies Strengthen Business Case for High Content Screening Adoption Increasing Focus on Personalized Medicine Expands Addressable Market Opportunity for HCS Technological Innovations in Cell-Based Assays Drive Market Growth Growing Use of HCS in Genomics and Proteomics Accelerates Market Penetration Integration of AI and Machine Learning in HCS Throws the Spotlight on Enhanced Data Analysis and Prediction Rising Investment in Biotechnology and Life Sciences Expands Market Scope for HCS Solutions Advances in Miniaturization and Microfluidics Propel Development of High-Performance HCS Systems Focus on Reducing Drug Development Costs and Time-to-Market Spurt Demand for HCS Technologies Increasing Adoption of HCS in Academic and Research Institutions Development of Novel 3D Cell Cultures Expands Addressable Market Opportunity for HCS Advances in Fluorescence and High-Resolution Imaging Propel Growth in Precision Screening Applications Rising Demand for Toxicology Testing and Safety Assessment Drives Adoption of HCS Increasing Use of HCS in Stem Cell Research and Regenerative Medicine Expands Market Reach Development of User-Friendly and Scalable HCS Platforms Fuels Market Adoption Rising Importance of Target-Based and Phenotypic Screening Strengthens Business Case for HCS Growing Adoption of HCS in Cancer Research and Immuno-Oncology Expands Market Scope Focus on Enhancing Screening Efficiency and Throughput Drives Market Innovation FOCUS ON SELECT PLAYERS:Some of the 21 companies featured in this High Content Screening (HCS) market report include: BD Biosciences BioTek Instruments Inc. EMD Millipore Essen BioScience Evotec AG GE Healthcare Life Sciences Genedata AG IntelliCyt Corporation Molecular Devices Inc. PerkinElmer Inc. Thermo Fischer Scientific Inc. TTP LabTech Ltd. Yokogawa Electric Corporation For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment High Content Screening (HCS) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
TechCrunch
19-05-2025
- Business
- TechCrunch
Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe's genomics service and its bank of 15 million customers' personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe customer data to help drug discovery, and that it will 'prioritize the privacy, security, and ethical use of 23andMe's customer data.' 23andMe filed for bankruptcy protection in March after a data breach exposed the private and genetic data of 7 million customers throughout 2023. The company's stock price also plummeted to near-zero amid waning consumer interest in the company's DNA testing kits. 23andMe's founder and chief executive Anne Wojcicki resigned from the company following the company's collapse. After its filing, a federal bankruptcy court was appointed to oversee the sale of 23andMe's assets, sparking concerns that the stores of customer data could be sold to adversarial nations or unethical buyers. Regeneron said in its statement that as the named buyer in the bankruptcy auction, it 'intends to ensure compliance' with 23andMe's privacy policies and laws regarding customer data. The bankruptcy court is set to consider Regeneron's acquisition on June 17. Regeneron said it will not acquire 23andMe's Lemonaid Health business.
